drug

trastuzumab pamirtecan

1 story · latest Nov 3, 2026

Follow trastuzumab pamirtecan. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Codes: BNT323, DB-1303
Trials: 1 registered trial in coverage

Relationships

Developed by BioNTech SE

Timeline

Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFO

Nov 3Quarterly updateBioNTech SE C4 Therapeutics, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.